Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Novartis

12 shared events · Importance 3 · Last updated Sep 23, 2026

Importance
3
Shared Events
12
Actions
2
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
95
Regulatory
United States — Food and Drug Administration: The FDA granted the approval, expanding Pluvicto's use to earlier-stage metastatic prostate cancer, a regulatory decision that broadens treatment options and sets a precedent for radioligand therapies.
Novartis: Novartis received FDA approval to expand Pluvicto's indication to mHSPC, nearly doubling the eligible patient population and reinforcing its leadership in radioligand therapy. This is expected to drive future revenue growth, though the stock dipped 1.45% on the announcement.
Jul 31, 2026 · 6 articles
57
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
53
Regulatory
United States — Food and Drug Administration: The FDA granted final approval of ANI's ANDA for generic Everolimus Tablets for Oral Suspension, enabling U.S. market entry. The decision is a routine regulatory action with no direct market exposure for the agency itself.
Novartis: Novartis' Afinitor Disperz faces new generic competition from ANI's approved Everolimus Tablets for Oral Suspension. The affected franchise is small relative to Novartis' overall business, so the financial impact is limited.
Sep 23, 2026 · 7 articles
49
Regulatory
United States — Food and Drug Administration: The FDA granted accelerated approval for TRUTAKNA based on proteinuria reduction, with continued approval contingent on confirmatory data.
Novartis: Novartis' Fabhalta and Vanrafia are among the competitors to TRUTAKNA in IgAN.
Jul 07, 2026 · 6 articles
46
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration encourages the adoption of advanced manufacturing technologies and continuous production models, reinforcing the shift from reactive to proactive compliance strategies in the pharmaceutical industry.
Novartis: Novartis is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments, showcasing the industry's move towards Pharma 4.0.
Apr 07, 2026 · 8 articles
45
Business
United States — Food and Drug Administration: The FDA granted priority review to del-zota in DMD44 and is set to meet with Novartis on next steps for del-brax in FSHD, keeping the agency central to the remaining AOC pipeline.
Novartis: Novartis is the central entity of the event; the del-desiran Phase III failure and prior pelacarsen setback erased roughly $30 billion in market value and intensified investor scrutiny of its M&A strategy and pipeline.
Sep 08, 2026 · 21 articles
37
Business
United States — Food and Drug Administration: Reportedly rejected ITM-11's application over third-party manufacturing issues and approved Telix's Pixclara and Curium's Bexlutry; its approvals gate up to $250 million in milestone payments.
Novartis: Dominant radiopharmaceutical player with Pluvicto and Lutathera faces a more vertically integrated competitor as Telix absorbs ITM's isotope supply and neuroendocrine tumor pipeline.
Sep 21, 2026 · 6 articles
35
Business
United States — Food and Drug Administration: The FDA granted Fast Track designation to PentixaFor, facilitating its development and regulatory review.
Novartis: Novartis reported strong Pluvicto sales growth, indicating a booming radiopharma market that could benefit PentixaFor's launch.
Jul 15, 2026 · 10 articles
14
Business
United States — Food and Drug Administration: The FDA approved Palsonify in 2025, enabling its commercial availability. The agency's regulatory decisions are relevant to the value of the acquired assets.
Novartis: Competitor in acromegaly market.
Jul 06, 2026 · 34 articles
9
Business
United States — Food and Drug Administration: The FDA declined to approve Lantheus' LNTH-2501 application due to manufacturing issues, a setback for Lantheus' pipeline.
Novartis: Novartis is mentioned as the maker of Pluvicto, a competitor to a Lantheus-Eli Lilly therapeutic that was abandoned.
Aug 03, 2026 · 7 articles
0
Business
Apr 27, 2026 · 7 articles
0
Tech
Novartis: Novartis partnered with Dr. Carl H. June, leading to the development and FDA approval of Tisagenlecleucel, the first CAR-T therapy, which significantly boosted the company's position in advanced cancer treatments.
Jun 16, 2026 · 8 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Novartis interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.